Treatment of performance status 2 patients with advanced non-small-cell lung cancer: What we know and what we don't know

Alfredo Tartarone, Michele Aleta

Research output: Contribution to journalArticlepeer-review

Abstract

Performance status (PS)2 patients with advanced non-small-cell lung cancer have been historically excluded from clinical trials, and scant-data are available to guide clinical practice. As in other types of cancer, PS represents a recognized prognostic factor, and the life expectancy for PS2 patients is nearly half that of the PSO/I patients. Even if single-agent chemotherapy still remains the reference treatment, recent data suggest a role for new agents or combination chemotherapy in these patients. A large Phase III randomized trial comparing single-agent versus combination chemotherapy is strongly needed.

Original languageEnglish
Pages (from-to)837-841
Number of pages5
JournalFuture Oncology
Volume5
Issue number6
DOIs
Publication statusPublished - 2009

Keywords

  • Bevacizumab
  • Chemotherapy
  • Erlotinib
  • Non-small-cell lung cancer
  • Paclitaxel poliglumex
  • PS2 patients
  • Targeted agents

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Treatment of performance status 2 patients with advanced non-small-cell lung cancer: What we know and what we don't know'. Together they form a unique fingerprint.

Cite this